Global Neisseria meningitidis Infections Drug Market

Neisseria meningitidis Infections Drug Comprehensive Study by Type (Penicillin, Ampicillin, Ceftriaxone), End-users (Hospital, Clinic, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) Players and Region - Global Market Outlook to 2026

Neisseria meningitidis Infections Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Neisseria meningitidis Infections Drug Market?

Meningococcal meningitis is a bacterial form of meningitis, a serious infection of the thin lining that surrounds the brain and spinal cord caused by Neisseria meningitidis, often referred to as meningococcus, a Gram-negative bacterium. It causes significant morbidity and mortality in children and young adults worldwide through an epidemic or sporadic meningitis and/or septicemia. According to the World Health Organization (WHO), meningococcal meningitis is observed worldwide but the highest burden of the disease is in the meningitis belt of sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east. Around 30 000 cases are still reported each year from that area. A range of antibiotics are used for the treatment of meningitis such as penicillin, ampicillin and ceftriaxone.

The market study is being classified by Type (Penicillin, Ampicillin and Ceftriaxone) and major geographies with country level break-up.

Beijing Minhai Biotechnology Co Ltd (China), GlaxoSmithKline Plc (United Kingdom), ImmunoBiology Ltd (United Kingdom), JN-International Medical Corp (United States), MGB Biopharma Ltd (United Kingdom), Panacea Biotec Ltd (India), Pfizer Inc (United States), Sanofi Pasteur SA (France), Serum Institute of India Ltd (India) and Wellstat Therapeutics Corporation (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Biological E Ltd (India) and China National Pharmaceutical Group Corp (China).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Neisseria meningitidis Infections Drug market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Neisseria meningitidis Infections Drug market by Type, Application and Region.

On the basis of geography, the market of Neisseria meningitidis Infections Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Meningococcal meningitis
  • Increased Number of Hospitals and Clinics

Market Trend
  • Growing Focus on Preventive Health Care

Restraints
  • Fluctuations in the Raw Material Prices

Opportunities
  • Increasing Number of Regulatory Approvals
  • Growth in the Health Care Industry

Challenges
  • Stringent Rules and Regulations of the Governments





Key Target Audience
Neisseria meningitidis Infections Drug Manufacturers, Raw Material Suppliers, Distributors and End-users

Report Objectives / Segmentation Covered

By Type
  • Penicillin
  • Ampicillin
  • Ceftriaxone
By End-users
  • Hospital
  • Clinic
  • Others

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Meningococcal meningitis
      • 3.2.2. Increased Number of Hospitals and Clinics
    • 3.3. Market Challenges
      • 3.3.1. Stringent Rules and Regulations of the Governments
    • 3.4. Market Trends
      • 3.4.1. Growing Focus on Preventive Health Care
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neisseria meningitidis Infections Drug, by Type, End-users, Distribution Channel and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Neisseria meningitidis Infections Drug (Value)
      • 5.2.1. Global Neisseria meningitidis Infections Drug by: Type (Value)
        • 5.2.1.1. Penicillin
        • 5.2.1.2. Ampicillin
        • 5.2.1.3. Ceftriaxone
      • 5.2.2. Global Neisseria meningitidis Infections Drug by: End-users (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Others
      • 5.2.3. Global Neisseria meningitidis Infections Drug by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacy
        • 5.2.3.2. Retail Pharmacy
        • 5.2.3.3. Online Pharmacy
        • 5.2.3.4. Others
      • 5.2.4. Global Neisseria meningitidis Infections Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Neisseria meningitidis Infections Drug (Volume)
      • 5.3.1. Global Neisseria meningitidis Infections Drug by: Type (Volume)
        • 5.3.1.1. Penicillin
        • 5.3.1.2. Ampicillin
        • 5.3.1.3. Ceftriaxone
      • 5.3.2. Global Neisseria meningitidis Infections Drug by: End-users (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Clinic
        • 5.3.2.3. Others
      • 5.3.3. Global Neisseria meningitidis Infections Drug by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacy
        • 5.3.3.2. Retail Pharmacy
        • 5.3.3.3. Online Pharmacy
        • 5.3.3.4. Others
      • 5.3.4. Global Neisseria meningitidis Infections Drug Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Neisseria meningitidis Infections Drug (Price)
      • 5.4.1. Global Neisseria meningitidis Infections Drug by: Type (Price)
  • 6. Neisseria meningitidis Infections Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Beijing Minhai Biotechnology Co Ltd (China)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. ImmunoBiology Ltd (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. JN-International Medical Corp (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. MGB Biopharma Ltd (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Panacea Biotec Ltd (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi Pasteur SA (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Serum Institute of India Ltd (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Wellstat Therapeutics Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Neisseria meningitidis Infections Drug Sale, by Type, End-users, Distribution Channel and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Neisseria meningitidis Infections Drug (Value)
      • 7.2.1. Global Neisseria meningitidis Infections Drug by: Type (Value)
        • 7.2.1.1. Penicillin
        • 7.2.1.2. Ampicillin
        • 7.2.1.3. Ceftriaxone
      • 7.2.2. Global Neisseria meningitidis Infections Drug by: End-users (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Others
      • 7.2.3. Global Neisseria meningitidis Infections Drug by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacy
        • 7.2.3.2. Retail Pharmacy
        • 7.2.3.3. Online Pharmacy
        • 7.2.3.4. Others
      • 7.2.4. Global Neisseria meningitidis Infections Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Neisseria meningitidis Infections Drug (Volume)
      • 7.3.1. Global Neisseria meningitidis Infections Drug by: Type (Volume)
        • 7.3.1.1. Penicillin
        • 7.3.1.2. Ampicillin
        • 7.3.1.3. Ceftriaxone
      • 7.3.2. Global Neisseria meningitidis Infections Drug by: End-users (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Clinic
        • 7.3.2.3. Others
      • 7.3.3. Global Neisseria meningitidis Infections Drug by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacy
        • 7.3.3.2. Retail Pharmacy
        • 7.3.3.3. Online Pharmacy
        • 7.3.3.4. Others
      • 7.3.4. Global Neisseria meningitidis Infections Drug Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Neisseria meningitidis Infections Drug (Price)
      • 7.4.1. Global Neisseria meningitidis Infections Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neisseria meningitidis Infections Drug: by Type(USD Million)
  • Table 2. Neisseria meningitidis Infections Drug Penicillin , by Region USD Million (2015-2020)
  • Table 3. Neisseria meningitidis Infections Drug Ampicillin , by Region USD Million (2015-2020)
  • Table 4. Neisseria meningitidis Infections Drug Ceftriaxone , by Region USD Million (2015-2020)
  • Table 5. Neisseria meningitidis Infections Drug: by End-users(USD Million)
  • Table 6. Neisseria meningitidis Infections Drug Hospital , by Region USD Million (2015-2020)
  • Table 7. Neisseria meningitidis Infections Drug Clinic , by Region USD Million (2015-2020)
  • Table 8. Neisseria meningitidis Infections Drug Others , by Region USD Million (2015-2020)
  • Table 9. Neisseria meningitidis Infections Drug: by Distribution Channel(USD Million)
  • Table 10. Neisseria meningitidis Infections Drug Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 11. Neisseria meningitidis Infections Drug Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 12. Neisseria meningitidis Infections Drug Online Pharmacy , by Region USD Million (2015-2020)
  • Table 13. Neisseria meningitidis Infections Drug Others , by Region USD Million (2015-2020)
  • Table 14. South America Neisseria meningitidis Infections Drug, by Country USD Million (2015-2020)
  • Table 15. South America Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 16. South America Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 17. South America Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 18. Brazil Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 19. Brazil Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 20. Brazil Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 21. Argentina Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 22. Argentina Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 23. Argentina Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 24. Rest of South America Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 25. Rest of South America Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 26. Rest of South America Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 27. Asia Pacific Neisseria meningitidis Infections Drug, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 29. Asia Pacific Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 30. Asia Pacific Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 31. China Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 32. China Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 33. China Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 34. Japan Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 35. Japan Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 36. Japan Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 37. India Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 38. India Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 39. India Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 40. South Korea Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 41. South Korea Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 42. South Korea Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 43. Taiwan Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 44. Taiwan Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 45. Taiwan Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 46. Australia Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 47. Australia Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 48. Australia Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 52. Europe Neisseria meningitidis Infections Drug, by Country USD Million (2015-2020)
  • Table 53. Europe Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 54. Europe Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 55. Europe Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 56. Germany Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 57. Germany Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 58. Germany Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 59. France Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 60. France Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 61. France Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 62. Italy Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 63. Italy Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 64. Italy Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 65. United Kingdom Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 66. United Kingdom Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 67. United Kingdom Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 68. Netherlands Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 69. Netherlands Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 70. Netherlands Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 71. Rest of Europe Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 72. Rest of Europe Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 73. Rest of Europe Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 74. MEA Neisseria meningitidis Infections Drug, by Country USD Million (2015-2020)
  • Table 75. MEA Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 76. MEA Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 77. MEA Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 78. Middle East Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 79. Middle East Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 80. Middle East Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 81. Africa Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 82. Africa Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 83. Africa Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 84. North America Neisseria meningitidis Infections Drug, by Country USD Million (2015-2020)
  • Table 85. North America Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 86. North America Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 87. North America Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 88. United States Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 89. United States Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 90. United States Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 91. Canada Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 92. Canada Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 93. Canada Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 94. Mexico Neisseria meningitidis Infections Drug, by Type USD Million (2015-2020)
  • Table 95. Mexico Neisseria meningitidis Infections Drug, by End-users USD Million (2015-2020)
  • Table 96. Mexico Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2015-2020)
  • Table 97. Neisseria meningitidis Infections Drug Sales: by Type(K Units)
  • Table 98. Neisseria meningitidis Infections Drug Sales Penicillin , by Region K Units (2015-2020)
  • Table 99. Neisseria meningitidis Infections Drug Sales Ampicillin , by Region K Units (2015-2020)
  • Table 100. Neisseria meningitidis Infections Drug Sales Ceftriaxone , by Region K Units (2015-2020)
  • Table 101. Neisseria meningitidis Infections Drug Sales: by End-users(K Units)
  • Table 102. Neisseria meningitidis Infections Drug Sales Hospital , by Region K Units (2015-2020)
  • Table 103. Neisseria meningitidis Infections Drug Sales Clinic , by Region K Units (2015-2020)
  • Table 104. Neisseria meningitidis Infections Drug Sales Others , by Region K Units (2015-2020)
  • Table 105. Neisseria meningitidis Infections Drug Sales: by Distribution Channel(K Units)
  • Table 106. Neisseria meningitidis Infections Drug Sales Hospital Pharmacy , by Region K Units (2015-2020)
  • Table 107. Neisseria meningitidis Infections Drug Sales Retail Pharmacy , by Region K Units (2015-2020)
  • Table 108. Neisseria meningitidis Infections Drug Sales Online Pharmacy , by Region K Units (2015-2020)
  • Table 109. Neisseria meningitidis Infections Drug Sales Others , by Region K Units (2015-2020)
  • Table 110. South America Neisseria meningitidis Infections Drug Sales, by Country K Units (2015-2020)
  • Table 111. South America Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 112. South America Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 113. South America Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 114. Brazil Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 115. Brazil Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 116. Brazil Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 117. Argentina Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 118. Argentina Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 119. Argentina Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 120. Rest of South America Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 121. Rest of South America Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 122. Rest of South America Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 123. Asia Pacific Neisseria meningitidis Infections Drug Sales, by Country K Units (2015-2020)
  • Table 124. Asia Pacific Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 125. Asia Pacific Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 126. Asia Pacific Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 127. China Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 128. China Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 129. China Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 130. Japan Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 131. Japan Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 132. Japan Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 133. India Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 134. India Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 135. India Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 136. South Korea Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 137. South Korea Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 138. South Korea Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 139. Taiwan Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 140. Taiwan Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 141. Taiwan Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 142. Australia Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 143. Australia Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 144. Australia Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 145. Rest of Asia-Pacific Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 146. Rest of Asia-Pacific Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 147. Rest of Asia-Pacific Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 148. Europe Neisseria meningitidis Infections Drug Sales, by Country K Units (2015-2020)
  • Table 149. Europe Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 150. Europe Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 151. Europe Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 152. Germany Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 153. Germany Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 154. Germany Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 155. France Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 156. France Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 157. France Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 158. Italy Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 159. Italy Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 160. Italy Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 161. United Kingdom Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 162. United Kingdom Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 163. United Kingdom Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 164. Netherlands Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 165. Netherlands Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 166. Netherlands Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 167. Rest of Europe Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 168. Rest of Europe Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 169. Rest of Europe Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 170. MEA Neisseria meningitidis Infections Drug Sales, by Country K Units (2015-2020)
  • Table 171. MEA Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 172. MEA Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 173. MEA Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 174. Middle East Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 175. Middle East Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 176. Middle East Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 177. Africa Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 178. Africa Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 179. Africa Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 180. North America Neisseria meningitidis Infections Drug Sales, by Country K Units (2015-2020)
  • Table 181. North America Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 182. North America Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 183. North America Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 184. United States Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 185. United States Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 186. United States Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 187. Canada Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 188. Canada Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 189. Canada Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 190. Mexico Neisseria meningitidis Infections Drug Sales, by Type K Units (2015-2020)
  • Table 191. Mexico Neisseria meningitidis Infections Drug Sales, by End-users K Units (2015-2020)
  • Table 192. Mexico Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 193. Neisseria meningitidis Infections Drug: by Type(USD/Units)
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Neisseria meningitidis Infections Drug: by Type(USD Million)
  • Table 205. Neisseria meningitidis Infections Drug Penicillin , by Region USD Million (2021-2026)
  • Table 206. Neisseria meningitidis Infections Drug Ampicillin , by Region USD Million (2021-2026)
  • Table 207. Neisseria meningitidis Infections Drug Ceftriaxone , by Region USD Million (2021-2026)
  • Table 208. Neisseria meningitidis Infections Drug: by End-users(USD Million)
  • Table 209. Neisseria meningitidis Infections Drug Hospital , by Region USD Million (2021-2026)
  • Table 210. Neisseria meningitidis Infections Drug Clinic , by Region USD Million (2021-2026)
  • Table 211. Neisseria meningitidis Infections Drug Others , by Region USD Million (2021-2026)
  • Table 212. Neisseria meningitidis Infections Drug: by Distribution Channel(USD Million)
  • Table 213. Neisseria meningitidis Infections Drug Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 214. Neisseria meningitidis Infections Drug Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 215. Neisseria meningitidis Infections Drug Online Pharmacy , by Region USD Million (2021-2026)
  • Table 216. Neisseria meningitidis Infections Drug Others , by Region USD Million (2021-2026)
  • Table 217. South America Neisseria meningitidis Infections Drug, by Country USD Million (2021-2026)
  • Table 218. South America Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 219. South America Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 220. South America Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 221. Brazil Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 222. Brazil Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 223. Brazil Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 224. Argentina Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 225. Argentina Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 226. Argentina Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 227. Rest of South America Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 228. Rest of South America Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 229. Rest of South America Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 230. Asia Pacific Neisseria meningitidis Infections Drug, by Country USD Million (2021-2026)
  • Table 231. Asia Pacific Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 232. Asia Pacific Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 233. Asia Pacific Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 234. China Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 235. China Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 236. China Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 237. Japan Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 238. Japan Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 239. Japan Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 240. India Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 241. India Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 242. India Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 243. South Korea Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 244. South Korea Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 245. South Korea Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 246. Taiwan Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 247. Taiwan Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 248. Taiwan Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 249. Australia Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 250. Australia Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 251. Australia Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 252. Rest of Asia-Pacific Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 253. Rest of Asia-Pacific Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 254. Rest of Asia-Pacific Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 255. Europe Neisseria meningitidis Infections Drug, by Country USD Million (2021-2026)
  • Table 256. Europe Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 257. Europe Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 258. Europe Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 259. Germany Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 260. Germany Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 261. Germany Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 262. France Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 263. France Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 264. France Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 265. Italy Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 266. Italy Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 267. Italy Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 268. United Kingdom Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 269. United Kingdom Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 270. United Kingdom Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 271. Netherlands Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 272. Netherlands Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 273. Netherlands Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 274. Rest of Europe Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 275. Rest of Europe Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 276. Rest of Europe Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 277. MEA Neisseria meningitidis Infections Drug, by Country USD Million (2021-2026)
  • Table 278. MEA Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 279. MEA Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 280. MEA Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 281. Middle East Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 282. Middle East Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 283. Middle East Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 284. Africa Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 285. Africa Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 286. Africa Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 287. North America Neisseria meningitidis Infections Drug, by Country USD Million (2021-2026)
  • Table 288. North America Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 289. North America Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 290. North America Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 291. United States Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 292. United States Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 293. United States Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 294. Canada Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 295. Canada Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 296. Canada Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 297. Mexico Neisseria meningitidis Infections Drug, by Type USD Million (2021-2026)
  • Table 298. Mexico Neisseria meningitidis Infections Drug, by End-users USD Million (2021-2026)
  • Table 299. Mexico Neisseria meningitidis Infections Drug, by Distribution Channel USD Million (2021-2026)
  • Table 300. Neisseria meningitidis Infections Drug Sales: by Type(K Units)
  • Table 301. Neisseria meningitidis Infections Drug Sales Penicillin , by Region K Units (2021-2026)
  • Table 302. Neisseria meningitidis Infections Drug Sales Ampicillin , by Region K Units (2021-2026)
  • Table 303. Neisseria meningitidis Infections Drug Sales Ceftriaxone , by Region K Units (2021-2026)
  • Table 304. Neisseria meningitidis Infections Drug Sales: by End-users(K Units)
  • Table 305. Neisseria meningitidis Infections Drug Sales Hospital , by Region K Units (2021-2026)
  • Table 306. Neisseria meningitidis Infections Drug Sales Clinic , by Region K Units (2021-2026)
  • Table 307. Neisseria meningitidis Infections Drug Sales Others , by Region K Units (2021-2026)
  • Table 308. Neisseria meningitidis Infections Drug Sales: by Distribution Channel(K Units)
  • Table 309. Neisseria meningitidis Infections Drug Sales Hospital Pharmacy , by Region K Units (2021-2026)
  • Table 310. Neisseria meningitidis Infections Drug Sales Retail Pharmacy , by Region K Units (2021-2026)
  • Table 311. Neisseria meningitidis Infections Drug Sales Online Pharmacy , by Region K Units (2021-2026)
  • Table 312. Neisseria meningitidis Infections Drug Sales Others , by Region K Units (2021-2026)
  • Table 313. South America Neisseria meningitidis Infections Drug Sales, by Country K Units (2021-2026)
  • Table 314. South America Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 315. South America Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 316. South America Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 317. Brazil Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 318. Brazil Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 319. Brazil Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 320. Argentina Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 321. Argentina Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 322. Argentina Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 323. Rest of South America Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 324. Rest of South America Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 325. Rest of South America Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 326. Asia Pacific Neisseria meningitidis Infections Drug Sales, by Country K Units (2021-2026)
  • Table 327. Asia Pacific Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 328. Asia Pacific Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 329. Asia Pacific Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 330. China Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 331. China Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 332. China Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 333. Japan Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 334. Japan Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 335. Japan Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 336. India Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 337. India Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 338. India Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 339. South Korea Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 340. South Korea Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 341. South Korea Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 342. Taiwan Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 343. Taiwan Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 344. Taiwan Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 345. Australia Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 346. Australia Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 347. Australia Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 348. Rest of Asia-Pacific Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 349. Rest of Asia-Pacific Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 350. Rest of Asia-Pacific Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 351. Europe Neisseria meningitidis Infections Drug Sales, by Country K Units (2021-2026)
  • Table 352. Europe Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 353. Europe Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 354. Europe Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 355. Germany Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 356. Germany Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 357. Germany Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 358. France Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 359. France Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 360. France Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 361. Italy Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 362. Italy Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 363. Italy Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 364. United Kingdom Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 365. United Kingdom Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 366. United Kingdom Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 367. Netherlands Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 368. Netherlands Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 369. Netherlands Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 370. Rest of Europe Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 371. Rest of Europe Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 372. Rest of Europe Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 373. MEA Neisseria meningitidis Infections Drug Sales, by Country K Units (2021-2026)
  • Table 374. MEA Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 375. MEA Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 376. MEA Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 377. Middle East Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 378. Middle East Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 379. Middle East Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 380. Africa Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 381. Africa Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 382. Africa Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 383. North America Neisseria meningitidis Infections Drug Sales, by Country K Units (2021-2026)
  • Table 384. North America Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 385. North America Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 386. North America Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 387. United States Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 388. United States Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 389. United States Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 390. Canada Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 391. Canada Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 392. Canada Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 393. Mexico Neisseria meningitidis Infections Drug Sales, by Type K Units (2021-2026)
  • Table 394. Mexico Neisseria meningitidis Infections Drug Sales, by End-users K Units (2021-2026)
  • Table 395. Mexico Neisseria meningitidis Infections Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 396. Neisseria meningitidis Infections Drug: by Type(USD/Units)
  • Table 397. Research Programs/Design for This Report
  • Table 398. Key Data Information from Secondary Sources
  • Table 399. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neisseria meningitidis Infections Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Neisseria meningitidis Infections Drug: by End-users USD Million (2015-2020)
  • Figure 6. Global Neisseria meningitidis Infections Drug: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 8. Asia Pacific Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 9. Europe Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 10. MEA Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 11. North America Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 12. Global Neisseria meningitidis Infections Drug: by Type K Units (2015-2020)
  • Figure 13. Global Neisseria meningitidis Infections Drug: by End-users K Units (2015-2020)
  • Figure 14. Global Neisseria meningitidis Infections Drug: by Distribution Channel K Units (2015-2020)
  • Figure 15. South America Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 16. Asia Pacific Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 17. Europe Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 18. MEA Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 19. North America Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 20. Global Neisseria meningitidis Infections Drug: by Type USD/Units (2015-2020)
  • Figure 21. Global Neisseria meningitidis Infections Drug share by Players 2020 (%)
  • Figure 22. Global Neisseria meningitidis Infections Drug share by Players (Top 3) 2020(%)
  • Figure 23. Global Neisseria meningitidis Infections Drug share by Players (Top 5) 2020(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Beijing Minhai Biotechnology Co Ltd (China) Revenue, Net Income and Gross profit
  • Figure 26. Beijing Minhai Biotechnology Co Ltd (China) Revenue: by Geography 2020
  • Figure 27. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 29. ImmunoBiology Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. ImmunoBiology Ltd (United Kingdom) Revenue: by Geography 2020
  • Figure 31. JN-International Medical Corp (United States) Revenue, Net Income and Gross profit
  • Figure 32. JN-International Medical Corp (United States) Revenue: by Geography 2020
  • Figure 33. MGB Biopharma Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. MGB Biopharma Ltd (United Kingdom) Revenue: by Geography 2020
  • Figure 35. Panacea Biotec Ltd (India) Revenue, Net Income and Gross profit
  • Figure 36. Panacea Biotec Ltd (India) Revenue: by Geography 2020
  • Figure 37. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer Inc (United States) Revenue: by Geography 2020
  • Figure 39. Sanofi Pasteur SA (France) Revenue, Net Income and Gross profit
  • Figure 40. Sanofi Pasteur SA (France) Revenue: by Geography 2020
  • Figure 41. Serum Institute of India Ltd (India) Revenue, Net Income and Gross profit
  • Figure 42. Serum Institute of India Ltd (India) Revenue: by Geography 2020
  • Figure 43. Wellstat Therapeutics Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 44. Wellstat Therapeutics Corporation (United States) Revenue: by Geography 2020
  • Figure 45. Global Neisseria meningitidis Infections Drug: by Type USD Million (2021-2026)
  • Figure 46. Global Neisseria meningitidis Infections Drug: by End-users USD Million (2021-2026)
  • Figure 47. Global Neisseria meningitidis Infections Drug: by Distribution Channel USD Million (2021-2026)
  • Figure 48. South America Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 49. Asia Pacific Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 50. Europe Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 51. MEA Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 52. North America Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 53. Global Neisseria meningitidis Infections Drug: by Type K Units (2021-2026)
  • Figure 54. Global Neisseria meningitidis Infections Drug: by End-users K Units (2021-2026)
  • Figure 55. Global Neisseria meningitidis Infections Drug: by Distribution Channel K Units (2021-2026)
  • Figure 56. South America Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 57. Asia Pacific Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 58. Europe Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 59. MEA Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 60. North America Neisseria meningitidis Infections Drug Share (%), by Country
  • Figure 61. Global Neisseria meningitidis Infections Drug: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Beijing Minhai Biotechnology Co Ltd (China)
  • GlaxoSmithKline Plc (United Kingdom)
  • ImmunoBiology Ltd (United Kingdom)
  • JN-International Medical Corp (United States)
  • MGB Biopharma Ltd (United Kingdom)
  • Panacea Biotec Ltd (India)
  • Pfizer Inc (United States)
  • Sanofi Pasteur SA (France)
  • Serum Institute of India Ltd (India)
  • Wellstat Therapeutics Corporation (United States)
Additional players considered in the study are as follows:
Biological E Ltd (India) , China National Pharmaceutical Group Corp (China)
Select User Access Type

Key Highlights of Report


Jan 2022 234 Pages 50 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Neisseria meningitidis Infections Drug Market Quantitative research analysis
Global Neisseria meningitidis Infections Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Meningococcal meningitis " is seen as one of major growth factors of Neisseria meningitidis Infections Drug Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
Global will lead Neisseria meningitidis Infections Drug Market in coming years.

Know More About Global Neisseria meningitidis Infections Drug Market Report?

Have a Query? Click Here

Other Related Reports

Cholera Vaccine Comprehensive Study by Type (Shanchol, Dukoral, Vaxchora, Others), End-users (Hospital, Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others), Serogroup ...
$ 3350
Anti Acne Drugs Comprehensive Study by Type (Accutane, Benzamycin, Cleocin T, Desquam-E, Erythromycin topical, Minocin, Retin-A), Mode of Administration (Injectable, Oral, Topical), Distribution Chan...
$ 3450
Aflatoxicosis Treatment Comprehensive Study by Type (Oxygen Therapy , Antihistamines , Antibiotics , Immunosuppressants , Blood Transfusion , Others ), Application (Hospitals , Clinics , Others ), Di...
$ 3450
Drug Screening Comprehensive Study by Type (Immunoassay Analyzer, Chromatography, Breathalyzer, Rapid Test Device, Assay Kits), Sample Type (Urine Samples, Breath Samples, Oral Fluid Samples, Hair Sa...
$ 3750
Pharmacy Automation Systems Comprehensive Study by Type (Automated Medication Dispensing Systems, Decentralized Automated Dispensing Systems, Automated Packaging and Labeling Systems, Automated Table...
$ 3750
Propofol Comprehensive Study by Type (Local Anaesthesia, General Anesthesia), Application (Medical Uses, Other Uses), Route of Administration (Intravenous, Inhalational) Players and Region - Global M...
$ 3500